This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Market Need
There are a significant number of complex investigational biotherapeutic products in development such as monoclonal and bi-specific antibodies, fusion proteins and antibody fragments which cross a broad range of clinically important indications. These products often require a high therapeutic dose and low volume subcutaneous injection delivery is preferred for patient convenience, compliance and reduction of overall healthcare costs. This leads to a need for very highly concentrated formulations of the therapeutic protein. Achieving stable aqueous formulations of therapeutics at high concentration can be exceptionally challenging, often leading to a considerable increase in the rate of aggregation, particle formation and high viscosity which significantly limits the injectability of the product.
What Arecor can do
Our Arestat™ technology offers a series of formulation options that have been specifically designed to overcome challenges associated with delivering stable aqueous formulations of high concentration proteins. In particular, the technology, addresses:
- Aggregation control
- Viscosity reduction
- Improved chemical instability